

Full text open access online (Since 2001)



Kamla-Raj IJHG 2023

PRINT: ISSN 0972-3757 ONLINE: ISSN 2456-6330

Int J Hum Genet, 24(1): 12-17 (2023)

DOI: 10.31901/24566322.2023/24.01.869

## **A Case of Successful Transformation of Unresectable Liver Cancer after TACE Combined with Apatinib and Camrelizumab**

**Jianwei Xiong, Qiang Li, Tao Tang, Lixin Zhang, Bao Ying, Kaifeng Zhao,  
Yongfu Xiong, Jingdong Li and Guo Wu\***

*Department of Hepatobiliary Surgery, Institute of Hepatobiliary-Pancreatic-Intestinal of  
North Sichuan Medical College, Nanchong 637000, Sichuan Province, P.R. China*

**KEYWORDS** Apatinib. Camrelizumab Injection. Combination Therapy. Hepatectomy. Liver Cancer

**ABSTRACT** Hepatocellular carcinoma (HCC) is a common malignant tumour of the digestive system with gradual onset, and the survival rate is low in patients with advanced HCC. This case reports a 33-year-old woman diagnosed with right hepatic lobe malignancy with portal vein tumour thrombus. The patient has preoperatively taken transarterial chemoembolization (TACE) combined with Apatinib and Camrelizumab immunotherapy, which led to a significant reduction in the volume of the tumour and a reduction in the quantity of tumour markers. The patient was treated by right hemihepatectomy after evaluation, and postoperative pathological examination showed that the patient's hepatocellular carcinoma with portal vein tumour thrombus was completely necrotic. TACE combined with Camrelizumab immunotherapy was continued after operation. As follow-up, tumour markers continued to decrease, and no tumour recurrence or distant metastasis have taken place. Data of the case suggests that combined transformation therapy could be a boon for advanced unresectable HCC patients.